A Randomized Double-Blind Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Brief description of study
To determine if adding atezolizumab to a paclitaxel, trastuzumab, and pertuzumab improves survival.
Clinical Study Identifier: s19-01008
ClinicalTrials.gov Identifier: NCT03199885
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
